Summary of COVID-19 zenuzolac studies

1. Kane et al., Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection

132 patient zenuzolac late treatment RCT: 200% higher mortality (p=0.34), 1% worse recovery (p=0.99), and 1% shorter hospitalization (p=0.87).
RCT 132 hospitalized COVID-19 patients showing no significant difference in outcomes with zenuzolac (GLS-1027) treatment.
Apr 2025, NCT04590547, https://clinicaltrials.gov/study/NCT04590547, https://c19p.org/kane